STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Amycretin

Also known as

Zenagamtide (INN / public naming; same molecule) · NNC0487-0111 · NN9487 / NN 9487 (development code) · Novo amycretin · Unimolecular amylin + GLP-1 dual agonist · GLP-1 / amylin / calcitonin receptor agonist (trial framing) · Oral amycretin (SNAC tablet discussion) · Subcutaneous amycretin (once-weekly)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Some talk Systemic SubQ / Oral Metabolic / GLP-1 class

Systemic GLP-1/amylin dual-agonist peptide for appetite and metabolic research; weekly SubQ and daily oral trial formulations.

What people say A single-chain GLP-1/amylin peptide studied for quieter appetite, earlier fullness and weight/glucose change. Amycretin combines two pathways in one molecule; it is not CagriSema or an approved consumer product. Doses people talk about
Obesity SubQ targets1.25 / 5 / 20 / 60 mg weekly

20 / 28 / 36 / 36 weeks total; final maintenance about 12 weeks. Earlier starting doses are separate study phases.

Oral trial targets50–100 mg once daily

SNAC tablets in 12-week exploration; 100 mg was two 50 mg tablets as one daily dose, reached through trial titration.

T2D dose-finding0.4–40 mg weekly SubQ / 6–50 mg daily oral

Separate SC groups: 0.4, 1.5, 5, 10, 20, 40 mg; oral groups: 6, 25, 50 mg. Not the 60 mg obesity arm.

Trial targets after study titration, not interchangeable products or a self-use progression; the full notes retain single-dose, lower-dose and T2D arms.

Half-life & effect duration

Half-life in the body
  • Injected · secondary estimateAbout 4 days
  • Oral · secondary estimateAbout 92–100 hours
Felt duration people report
  • After injectionsFeeling quieter or disconnected for 1–2 days in one trial account
  • During continued treatmentQuieter hunger and persistent constipation; no energy boost
Timing context & sources
How it may feel Quieter hunger and smaller meals are the draw. One trial account also reports persistent constipation and 1–2 days of feeling disconnected after injections, without extra energy. Weight and HbA1c changes are longer-term measurements, not an immediate feeling.
Cycles people discuss Trial courses run for months: oral exploration to 12 weeks and obesity SubQ arms to 20–36 weeks, with titration then maintenance. On/off and restart lore is not an established amycretin schedule. Timing Weekly SubQ and daily oral are separate trial formulations. Fasting/food rules and restart advice are often borrowed from other oral GLP-1s; those analogies are not amycretin-specific instructions. Stacks Usually compared with CagriSema, tirzepatide or retatrutide, rather than combined. It already contains two appetite pathways; extra incretins/amylins add GI and interaction uncertainty. Watch for GI events (dominant): Nausea, vomiting, diarrhea, constipation, and decreased appetite drive the AE profile — consistent with GLP-1 and amylin agonists.
Related
CagrilintideCagriSemaSemaglutideTirzepatideRetatrutide

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A numerical human half-life was not verified from the accessible oral or SubQ trial abstracts.

Older notes quote about 4 days SubQ and 92–100 hours oral. Those numbers remain labeled secondary; weekly/daily schedules are not plasma measurements.

The numerical full-text PK tables were inaccessible in this pass. This is a bounded verification limit, not a claim that human PK does not exist.

Felt duration people report

One participant described 1–2 days of feeling quieter/disconnected after injections; appetite-benefit duration is not established.

The same account reports quieter hunger and persistent constipation during a 9-month trial, plus no energy boost in the follow-up.

Unverified single account, dose and injection depth unstated. This is a reported adverse-feeling interval, not satiety offset or a diagnosed mood effect.

  • Amycretin availability — self-described trial participant and follow-up (opens in a new tab)Top_Relief_4576 reply describing a 9-month Australian trial, 23 kg change and constipation; expanded same-author follow-up at /comment/nqnld60/?force-legacy-sct=1 describing injection day/next day, 1–2 days disconnected and no energy improvement.Identity, trial participation and product unverified; dose and injection depth unstated. Partner-observed quietness is not a diagnosed mood disorder, satiety offset, or measured PK. Original and visible expanded follow-up both read.

Other context in this card

  • Subcutaneous zenagamtide phase 2 T2D trial (2026) (opens in a new tab)Complete indexed abstract: Methods and Findings, read through Europe PMC PMID 42532080 core record; primary endpoint HbA1c at week 36, six SC maintenance groups.Abstract only, SC T2D population on metformin with/without SGLT2 inhibitor; not an oral trial or direct obesity-population comparison. No numerical half-life table in the accessible abstract.

What people say 19

  • Appetite / food noise (expected + discussed): Dual GLP-1 + amylin satiety → decreased appetite, earlier fullness, quieter meal drive — same qualitative story as CagriSema but one molecule. forum
  • vs CagriSema numbers (cross-trial only): Early SC amycretin ~22–24% at 36 weeks was compared in media to CagriSema ~20–23% at longer (e.g. 68-week) horizons — different populations, durations, and estimands; not a head-to-head. forum
  • vs mono GLP-1 / GIP–GLP / triple (forum ranking): Boards slot amycretin with next-gen duals after sema/tirz/reta maturity; oral path is a unique talking point vs injectable-only triples. forum
  • Body-comp caveat: Large mean % loss is not a muscle-sparing claim; protein + resistance training is the default mitigation talk under strong appetite suppression. forum
  • SC obesity phase 1b/2a design (Dahl et al., Lancet; NCT06064006): Single-center RCT; adults with overweight/obesity; n=125 (amycretin 101, placebo 24); once-weekly SC up to 36 weeks with last ~12 weeks at assigned maintenance. trial
  • SC 60 mg weekly (Part B, week 36): Estimated mean bodyweight change ~−24.3% vs ~−1.1% placebo — highest-dose arm and the headline figure in most coverage. trial
  • SC 20 mg weekly (Part C, week 36): ~−22.0% vs ~+1.9% placebo — nearly as large as 60 mg in this early dataset; often cited as the more “practical” high arm in commentary. trial
  • SC 5 mg weekly (Part D, week 28): ~−16.2% vs ~+2.3% placebo. trial
  • SC 1.25 mg weekly (Part E, week 20): ~−9.7% vs ~+2.0% placebo — lowest MAD maintenance still separated from placebo. trial
  • Dose–response pattern (obesity SC): Mean % loss rose with maintenance dose and observation length; no early plateau called out by investigators at last observation in these arms. trial
  • Oral phase 1 (Gasiorek et al., Lancet; NCT05369390): First-in-human daily oral amycretin with SNAC absorption enhancer; multi-part SAD/MAD up to 12 weeks in adults with overweight/obesity without diabetes. trial
  • Oral 50 mg/day (12 weeks): Mean bodyweight ~−10.4% vs roughly ~−1% to −1.2% placebo depending on summary. trial
  • Oral 2 × 50 mg/day (100 mg total daily, 12 weeks): Mean ~−13.1% vs ~−1% placebo — highest oral exploratory arm; investigators noted no apparent plateau by day 85. trial
  • T2D phase 2 SC (dose-finding, up to 36 weeks): Once-weekly arms commonly listed as 0.4, 1.5, 5, 10, 20, and 40 mg; dose-dependent HbA1c and weight effects reported. trial
  • T2D SC weight (toplines / ADA-style coverage): Up to ~−14.5% to ~−14.6% mean bodyweight at week 36 vs roughly ~−2.1% to −2.6% placebo (baseline mean weight often cited ~99 kg). trial
  • T2D SC glycemic: HbA1c reductions up to ~−1.7 to −1.8 percentage points from baselines around ~7.8%; large shares of participants hit HbA1c <7% in secondary coverage (exact % varies by arm/summary — check primary readout). trial
  • T2D oral arms (same phase 2 program): Daily oral dose groups commonly listed as 6, 25, and 50 mg for up to 36 weeks; weight loss up to ~−10.1% and HbA1c up to ~−1.5% in public toplines. trial
  • Enrollment scale (T2D phase 2): On the order of ~448 participants across nine active treatment arms (six SC + three oral) in sponsor/secondary reports. trial
  • Animals / preclinical: Mouse/rat models show weight reduction, lower energy intake, and improved insulin sensitivity supporting the dual-agonist design. animal

Doses people talk about 16

  • SC high-end discussion: 60 mg weekly is the top studied obesity arm; 20 mg delivered nearly comparable mean % loss in the same program — commentary often questions whether 60 mg is necessary. forum
  • Weekly vs daily choice (discussion): SC = once-weekly convenience; oral = daily tablet logistics + SNAC/fasting-style absorption rules often borrowed from other oral GLP-1s (exact commercial instructions not finalized). forum
  • mcg translation (community unit talk): 0.3 mg = 300 mcg; 1.25 mg = 1250 mcg; 5 mg = 5000 mcg; 20 mg = 20,000 mcg; 40–60 mg weekly are large absolute peptide masses vs classic research peptides — concentration math on any claimed research vial is error-prone. forum
  • SC single ascending (Part A): Separate exploratory single doses ~0.3 mg, 0.6 mg, and 1.0 mg to probe starting tolerability; this single-dose part is distinct from the weekly repeated-dose arms. trial
  • SC MAD start: Escalation typically began near ~0.3 mg once weekly before climbing toward assigned maintenance. trial
  • SC maintenance ladder (obesity phase 1b/2a): Assigned targets 1.25 mg (20 weeks total), 5 mg (28 weeks), 20 mg (36 weeks), and 60 mg (36 weeks); final maintenance held for the last ~12 weeks of each arm. trial
  • Oral SAD (phase 1 Part A): Single oral doses explored across roughly 1, 3, 6, 12, 18 (adaptive 12+6), and 25 mg. trial
  • Oral short MAD (Part B): Multiple ascending daily doses in the ~3 / 6 / 12 mg once-daily band (short multi-day blocks). trial
  • Oral exploratory tops: 50 mg/day and 100 mg/day (2 × 50 mg) are the 12-week efficacy-talk doses most cited. trial
  • T2D SC dose-finding band: Public summaries list once-weekly 0.4, 1.5, 5, 10, 20, and 40 mg (note: T2D high arm 40 mg differs from obesity exploration up to 60 mg). trial
  • Titration principle: Gradual step-ups are the safety theme across oral and SC programs; aggressive jumps track with worse GI. trial
  • Not DIY CagriSema math: Amycretin mg charts are not interchangeable with cagrilintide 2.4 + semaglutide 2.4 pairing or with mono cagri 0.25–4.5 mg ladders. trial
  • Framing: Published trial schedules, sponsor toplines, and secondary coverage only — educational ranges, not advice, not approved labeling, not a consumer protocol. forum
  • Oral 12-week fixed-titration arms (Parts C/D): Examples include escalation from ~3 mg toward 50 mg once daily; from ~6 mg toward 2 × 50 mg (two tablets as one daily dose); and from ~3 mg toward 2 × 25 mg — all with stepwise titration rather than a cold high start. trial
  • T2D oral dose-finding band: Daily 6, 25, and 50 mg groups reported in phase 2 multi-arm design. trial
  • Phase 3 dose uncertainty: Late-stage obesity (AMAZE) and T2D programs may pick different commercial targets than early maxima; do not assume 60 mg SC or 100 mg oral become the approved labels. trial

How it may feel 8

  • GI time course: Trial narratives describe events around up-titration and dose steps, often diminishing on a stable dose; most were mild–moderate and many resolved by study end. This is not universal: the reviewed trial participant described constipation throughout their course. trialforum
  • Days 1–7: The existing class-based framing is GI and satiety first — nausea, early fullness and appetite drop before meaningful scale change. Separately, one self-described Australian trial participant reported quieter hunger and persistent constipation across a 9-month trial; in a follow-up they described feeling quieter/disconnected on injection day and the next day (1–2 days), with no energy improvement. Dose was not stated. trialforum
  • Weeks 1–4 (titration start): Stepwise escalation window; hunger cues may reset while GI adapts; high starts without titration worsen tolerability in trial narratives. trial
  • Weeks 4–12 (oral exploratory): Phase 1 oral weight readouts land at 12 weeks with double-digit means at 50–100 mg/day; still early relative to multi-month obesity phase 3 designs. trial
  • Weeks 12–20 (low SC arm): 1.25 mg weekly ~−9.7% at week 20 — first solid SC timepoint many summaries cite. trial
  • Weeks 20–28 (mid SC): 5 mg arm ~−16.2% at week 28 with ~12-week maintenance hold at the end of that arm. trial
  • Weeks 28–36 (high SC): 20 mg and 60 mg arms pull further from placebo through week 36; ongoing separation without early plateau called out. trial
  • T2D 36-week readouts: Reported weight-loss means are smaller than in the non-diabetes obesity arms, a cross-population comparison rather than a guaranteed difference in how the drug feels. HbA1c is an objective glycemic endpoint, not a subjective sensation. trial

Cycles people discuss 10

  • No classic on/off cycle: Continuous weekly SC or daily oral while goals/clinical program continue; regain after stop is the class expectation. forum
  • Restart talk: Some discussions borrow lower-titration restarts after gaps from broader GLP-1/amylin GI practice. That is not an amycretin label or a restart instruction, and the reviewed abstracts do not establish a consumer restart schedule. forum
  • Chronic / ongoing model: Obesity and T2D programs treat multi-month continuous therapy as the design, not a 4–8 week PED-style blast. trial
  • Structure: Multi-week titration → multi-week (often ~12-week) maintenance hold at target inside early trials → longer phase 3 horizons expected. trial
  • Obesity SC windows: ~20 weeks (1.25 mg), ~28 weeks (5 mg), ~36 weeks (20 / 60 mg) in phase 1b/2a. trial
  • Oral exploratory window: Up to ~12 weeks in first-in-human multiparts for weight PD. trial
  • T2D mid-stage window: Up to ~36 weeks SC and oral dose-finding. trial
  • Phase 3 obesity (AMAZE program talk): Sponsor advanced oral + SC into late-stage weight management with initiation planned around early 2026; multi-trial AMAZE series discussed for obesity and comorbidities (e.g., maintenance, OSA, knee OA in registry/news coverage). trial
  • Long-term unknowns: Years-long safety, CV outcomes, and commercial dose selection remain phase 3 / post-marketing questions. trial
  • Phase 3 T2D: Novo communications after ADA 2026 zenagamtide readout planned phase 3 diabetes development (e.g., H2 2026 start framing). trial

Timing 10

  • Weekly SC implication: Multi-day exposure and multi-week build to steady state; early weeks understate later exposure and side risk after escalation. forum
  • Daily oral implication: Daily dosing for oral arms; meal/fasting and co-med timing rules are often discussed by analogy to other SNAC oral GLP-1s (e.g., oral semaglutide culture) until product-specific leaflets exist. forum
  • After last dose: Days to a few weeks of residual effects or side effects is class-based multi-day-half-life reasoning in the existing discussion, not an observed amycretin offset estimate. Prior exposure may matter; the reviewed participant account does not establish when appetite effects fully wear off. forum
  • Unimolecular PK sell: One absorption profile and one half-life vs co-administered cagri + sema with two independent PK curves. forum
  • Design intent: C18 diacid-based acylation on the GLP-1-related portion enables reversible albumin binding and a long systemic half-life supporting daily oral or weekly SC regimens. trial
  • SC elimination half-life (secondary reviews): Around ~4 days is retained as an older secondary-summary figure for the subcutaneous formulation. The accessible 2025 SC trial abstract reviewed here does not provide the numerical elimination table; weekly dosing alone does not validate that estimate. trial
  • Oral formulation half-life (secondary reviews): Roughly ~92–100 hours after absorption remains the older SNAC oral-summary figure. The accessible 2025 oral trial abstract reviewed here does not show the numerical half-life table; daily oral dosing is a regimen, not proof of a 24-hour plasma clock. trial
  • Preclinical PK lore: Patent/minipig discussions of C18/C20 fatty-acid linkers cite ~160–180 hour ranges as structural rationale for weekly potential — animal PK, not a human label claim. animal
  • Tmax / onset: Not a same-hour stimulant; satiety and GI lag absorption and distribution — exact public Tmax tables are sparse outside full papers. trial
  • Satiety vs dose-day peaks: Appetite mid-interval can differ from peak GI on escalation days; delayed gastric emptying is dual-pathway. trial

More on what it is 8

  • Why people search it: Early double-digit oral weight loss at 12 weeks and ~22–24% mean SC loss by week 36 in non-diabetes obesity arms, plus dual-pathway lore after CagriSema — positioned as a potential unimolecular rival to two-drug amylin+GLP-1 combos. forum
  • Unimolecular vs stack: Forums contrast “one shot/pill dual pathway” vs DIY cagri+sema or CagriSema pen logistics — unified half-life and ratio are the conceptual sell, not proven superiority in head-to-head phase 3 vs those agents yet. forum
  • Supply honesty: Proprietary clinical material only in legitimate programs; gray-market “amycretin/zenagamtide” powder or vials are identity/purity high-risk and are not trial product. forum
  • What it is: Novo Nordisk investigational unimolecular peptide that co-agonizes GLP-1 and amylin receptors in one chain (trial language also references calcitonin-receptor activity); developed as once-weekly SC and once-daily oral (SNAC co-formulated) candidates. trial
  • Names / codes: Development and news still widely use amycretin; zenagamtide is the INN-style public name on ADA 2026 and later Novo materials; codes include NNC0487-0111 and NN9487. Same molecule under different labels. trial
  • Mechanism (plain): One molecule covers GLP-1 appetite/glucose signaling plus amylin-pathway satiety (meal stop, portion cut, delayed emptying) with unified PK instead of two separate injectables. trial
  • Evidence bar: Human phase 1 oral (Lancet), phase 1b/2a SC obesity (Lancet), phase 2 T2D dose-finding (SC + oral arms; ADA 2026 zenagamtide readout) — denser than classic research peptides, still pre-approval. trial
  • What it is not: Not FDA/EMA approved; not CagriSema (cagrilintide + semaglutide two-drug combo); not tirzepatide (GIP/GLP-1) or retatrutide (triple); not a stimulant, GH secretagogue, or short-acting mealtime amylin like pramlintide. trial

Stacks 8

  • Already dual: GLP-1 + amylin in one molecule — stacking another full GLP-1 RA, dual (tirz), triple (reta), or CagriSema is widely framed as redundant polypharmacy with extra GI risk. forum
  • Vs CagriSema (comparison, not stack): Conceptual same dual pathway (amylin + GLP-1) but CagriSema is two drugs at fixed 2.4/2.4 mg; amycretin is unimolecular with its own mg chart — usually compared, not co-used. forum
  • Vs tirzepatide / retatrutide: Switch or “which next-gen” ranking talk dominates over combining; different receptor sets (GIP/GLP or GIP/GLP/glucagon vs GLP/amylin). forum
  • Vs mono semaglutide / liraglutide: Pipeline upgrade narrative after mono GLP-1 plateaus — not a documented co-admin protocol. forum
  • Lifestyle “stack”: Protein-forward intake + resistance training commonly credited for body-comp quality when trial-scale weight loss occurs. forum
  • Anti-nausea supports: Clinician-directed antiemetics, slower titration, hydration, and smaller lower-fat meals during escalation — class GI toolkit. forum
  • Amylin mono add-on lore does not apply cleanly: Adding separate cagrilintide or pramlintide on top of amycretin is not a studied regimen and is generally discouraged in dual-agonist discussions. forum
  • Gray-market blend risk: Pre-mixed research vials claiming amycretin + other incretins inherit unknown ratios and assays — pure community/vendor experimentation talk. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 15

  • Class GI / biliary / pancreatitis talk: Rare serious GI, gallbladder, and pancreatitis concerns are borrowed from the broader GLP-1 class; amycretin-specific long-term tables are still maturing in phase 3. forum
  • Hypoglycemia: Class-adjacent caution when background insulin or sulfonylureas are present; T2D trial backgrounds vary — not a “free” glucose drug. forum
  • Lean mass / under-eating: Strong dual satiety can collapse protein intake; training quality and bone/muscle concerns are community cautions under any large % loss. forum
  • Counterfeit / mislabel: Genuine supply is investigational Novo clinical material — gray-market “amycretin” or “zenagamtide” research listings carry high wrong-peptide and dose-error risk. forum
  • Polypharmacy risk: Stacking with other incretins/amylins multiplies GI and unknown interaction risk without RCT support. forum
  • GI events (dominant): Nausea, vomiting, diarrhea, constipation, and decreased appetite drive the AE profile — consistent with GLP-1 and amylin agonists. trial
  • SC obesity AE rates (published summaries): Among treated participants in phase 1b/2a coverage, nausea has been reported around ~82%, vomiting ~53%, and diarrhea ~41%, peaking during up-titration then often diminishing. trial
  • Oral phase 1 TEAE pattern: Treatment-emergent AEs in a large share of participants (coverage cites ~62% with ≥1 TEAE); GI was the plurality of events; all events mild or moderate in that first-in-human report; no deaths reported. trial
  • Severity / resolution: Majority mild–moderate; many GI events resolved by end of study on continued treatment. trial
  • Dose-related tolerability: Higher doses and aggressive escalation increase GI frequency — titration is a core safety theme, not optional flavor. trial
  • Discontinuations (SC obesity): ~33% withdrew overall; ~59% of withdrawals were for non-TEAE reasons (e.g., consent withdrawal, recreational drug use in study reports) — selection and retention effects matter when reading completer weight curves. trial
  • Heart rate: Increased heart rate reported in some SC trial summaries — monitor-class discussion. trial
  • Injection-site reactions: Mild–moderate local reactions possible with weekly SC. trial
  • Not risk-free: Strong mean % weight loss ≠ universal tolerability, durability, or regulatory approval. trial
  • Research-only framing: Not medical advice; not intended for consumption; discussed as investigational pharmacology and community lore. forum

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →